AU2010220132B2 - Activated leukocyte composition - Google Patents

Activated leukocyte composition Download PDF

Info

Publication number
AU2010220132B2
AU2010220132B2 AU2010220132A AU2010220132A AU2010220132B2 AU 2010220132 B2 AU2010220132 B2 AU 2010220132B2 AU 2010220132 A AU2010220132 A AU 2010220132A AU 2010220132 A AU2010220132 A AU 2010220132A AU 2010220132 B2 AU2010220132 B2 AU 2010220132B2
Authority
AU
Australia
Prior art keywords
leukocytes
composition
wound
cells
bag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010220132A
Other languages
English (en)
Other versions
AU2010220132A1 (en
Inventor
Eilat Bain
Marina Bubis
Orit Frenkel
Irene Ginis
Eilat Shinar
Mitchell Shirvan
Adi Zuloff-Shani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macrocure Ltd
Original Assignee
Macrocure Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrocure Ltd filed Critical Macrocure Ltd
Publication of AU2010220132A1 publication Critical patent/AU2010220132A1/en
Application granted granted Critical
Publication of AU2010220132B2 publication Critical patent/AU2010220132B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Surgery (AREA)
  • Materials Engineering (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
AU2010220132A 2009-03-05 2010-03-05 Activated leukocyte composition Ceased AU2010220132B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20929809P 2009-03-05 2009-03-05
US61/209,298 2009-03-05
US21158709P 2009-04-01 2009-04-01
US61/211,587 2009-04-01
PCT/IB2010/000882 WO2010100570A2 (en) 2009-03-05 2010-03-05 Activated leukocyte composition

Publications (2)

Publication Number Publication Date
AU2010220132A1 AU2010220132A1 (en) 2011-10-13
AU2010220132B2 true AU2010220132B2 (en) 2013-10-10

Family

ID=42710060

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010220132A Ceased AU2010220132B2 (en) 2009-03-05 2010-03-05 Activated leukocyte composition

Country Status (15)

Country Link
EP (2) EP2650001B1 (enExample)
JP (2) JP5713924B2 (enExample)
KR (1) KR101548783B1 (enExample)
CN (1) CN102438635B (enExample)
AU (1) AU2010220132B2 (enExample)
BR (1) BRPI1006759A2 (enExample)
CA (2) CA2867976A1 (enExample)
DK (1) DK2403509T3 (enExample)
ES (1) ES2428102T3 (enExample)
IL (1) IL214953A0 (enExample)
MX (1) MX2011009277A (enExample)
PL (1) PL2403509T3 (enExample)
RU (2) RU2015102067A (enExample)
WO (1) WO2010100570A2 (enExample)
ZA (1) ZA201107269B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8574902B2 (en) 2009-03-05 2013-11-05 Macrocure Ltd. Activated leukocyte composition and uses for wound healing
BR112013005610A2 (pt) * 2010-09-09 2019-09-24 Macrocure Ltd sobrenadante condicionado de leucócito, alcs, método para o tratamento de uma ferida, método para a inibição do surgimento de infecção em uma ferida, método, sobrenadante e produto
WO2013136182A1 (en) 2012-03-15 2013-09-19 Macrocure, Ltd. Activated immunostimulatory cell composition and uses thereof
RU2014140795A (ru) 2012-03-15 2016-05-10 Макрокьюэ, Лтд. Активированная иммуностимулирующая клеточная композиция, используемая для лечения инфекционных заболеваний
EP2781224A1 (en) * 2013-03-18 2014-09-24 Khorionyx Implantable preparations comrpsing globin insoluble at physiological pH and serum for regeneration of tissues and treatment of wounds.
CN107427535A (zh) 2015-02-16 2017-12-01 纳雅康医疗有限公司 经修饰的血凝块
GB201618106D0 (en) 2016-10-26 2016-12-07 Lift Biosciences Ltd Cancer-killing cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146890A (en) * 1994-07-03 2000-11-14 Danon; David Method and system for cultivating macrophages

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60120821A (ja) * 1983-12-05 1985-06-28 Asahi Chem Ind Co Ltd 悪性腫瘍治療用白血球刺激材および刺激方法
US4751001A (en) * 1984-09-24 1988-06-14 Becton Dickinson And Company Blood partitioning apparatus
JPH02167071A (ja) * 1988-12-19 1990-06-27 Terumo Corp 非ヒト動物由来白血球系細胞の分離材、分離器および分離方法
JPH07102151B2 (ja) * 1994-06-03 1995-11-08 中外製薬株式会社 新規なポリペプチドの製造法
IL110195A (en) * 1994-07-03 2003-10-31 David Danon Method and system for cultivating macrophages
JP3201610B2 (ja) * 1995-03-17 2001-08-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 腫瘍を処置する方法
JPH10259134A (ja) * 1997-01-16 1998-09-29 Sekisui Chem Co Ltd 創傷治癒促進剤
RU2143685C1 (ru) * 1998-05-19 1999-12-27 Коган Александр Харитонович Способ дифференциального подсчета гранулоцитов, моноцитов и лимфоцитов
EP1731175B1 (en) * 1998-11-12 2009-09-30 International Manufacturing Group, Inc. Hemostatic cross-linked dextran beads useful for rapid blood coagulation and hemostatis
AU2002353465B2 (en) * 2001-11-21 2008-10-16 Yeda Research And Development Co. Ltd. Process for the manufacture of human mononuclear phagocytic leukocytes
JP4108393B2 (ja) * 2002-07-15 2008-06-25 テルモ株式会社 細胞増殖剤の製造方法
JP4245324B2 (ja) * 2002-10-09 2009-03-25 旭化成クラレメディカル株式会社 単球の分離回収方法
EP2198873A1 (en) * 2008-12-18 2010-06-23 Aposcience AG Pharmaceutical preparation comprising supernatant of blood mononuclear cell culture
EP2201954A1 (en) * 2008-12-18 2010-06-30 Aposcience AG Pharmaceutical preparation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146890A (en) * 1994-07-03 2000-11-14 Danon; David Method and system for cultivating macrophages

Also Published As

Publication number Publication date
RU2011139016A (ru) 2013-04-10
KR101548783B1 (ko) 2015-08-31
WO2010100570A3 (en) 2010-12-16
RU2548741C2 (ru) 2015-04-20
CA2754190A1 (en) 2010-09-10
JP2015129180A (ja) 2015-07-16
RU2015102067A (ru) 2015-06-20
EP2403509B1 (en) 2013-08-21
ZA201107269B (en) 2014-03-26
CA2867976A1 (en) 2010-09-10
EP2403509A2 (en) 2012-01-11
DK2403509T3 (da) 2013-09-16
WO2010100570A2 (en) 2010-09-10
KR20120002530A (ko) 2012-01-05
EP2650001A1 (en) 2013-10-16
CN102438635A (zh) 2012-05-02
BRPI1006759A2 (pt) 2016-03-15
CN102438635B (zh) 2014-09-17
AU2010220132A1 (en) 2011-10-13
JP5713924B2 (ja) 2015-05-07
IL214953A0 (en) 2011-11-30
EP2650001B1 (en) 2016-09-07
ES2428102T3 (es) 2013-11-05
MX2011009277A (es) 2011-12-16
PL2403509T3 (pl) 2013-11-29
JP2012519681A (ja) 2012-08-30

Similar Documents

Publication Publication Date Title
US10226516B2 (en) Process, tube and device for the preparation of wound healant composition
EP2403509B1 (en) Activated leukocyte composition
US9439950B2 (en) Activated leukocyte conditioned supernatant and uses for wound healing
US9132154B2 (en) Activated leukocyte composition and uses for wound healing
WO2012115906A1 (en) Cell therapy for limiting overzealous inflammatory reactions in tissue healing
WO2016075542A1 (en) Methods for extended storage of activated leukocyte compositions
AU2013203115B2 (en) Process,tube and device for the preparation of wound healant composition
HK1252027B (en) Wound dressings, methods and apparatus for making same and storage and use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired